StockData
Humacyte, Inc. logo

Humacyte, Inc. (HUMA) stock

HUMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 2/30
$0.50−0.00 (-0.20%)

Close on Nov 18, 2026Market cap $138.90MP/E –Yield –

Humacyte gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

Humacyte's gross profit for the twelve months ending Jun 30, 2026 was -$10.49M, down 2390.4% year over year. For fiscal 2025 it was -$7.66M.

Annual gross profit

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$7.66M–
FY2024Dec 31, 2024$0–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$825.00K-1037.5%
Q1 FY2026Mar 31, 2026-$1.54M-517.0%
Q4 FY2025Dec 31, 2025-$8.62M–
Q3 FY2025Sep 30, 2025$493.00K–
Q2 FY2025Jun 30, 2025$88.00K–
Q1 FY2025Mar 31, 2025$370.00K–
Q4 FY2024Dec 31, 2024$0–
Q3 FY2024Sep 30, 2024$0–
Q2 FY2024Jun 30, 2024$0–
Q1 FY2024Mar 31, 2024$0–

More Humacyte figures

See a number that looks wrong?